Target intelligence / Profile preview

Coenzyme Q5, methyltransferase (COQ5)

Target
COQ5
Molecular classification
Enzyme, Methyltransferase, Mitochondrial protein
01

Overview

Coenzyme Q5, methyltransferase (COQ5) is a SAM-dependent methyltransferase enzyme located in the mitochondrial matrix, essential for the biosynthesis of ubiquinone (coenzyme Q10), a critical component of the mitochondrial electron transport chain responsible for ATP generation. COQ5 catalyzes the C-methylation of 2-decaprenyl-6-methoxy-1,4-benzoquinol (DDMQH2) to 2-decaprenyl-3-methyl-6-methoxy-1,4-benzoquinol (DMQH2), thus facilitating one of the final steps in the production of coenzyme Q10. Mutations in COQ5 can cause primary coenzyme Q10 deficiency leading to severe neurodevelopmental, neurological, and multi-organ dysfunctions. COQ5 is considered a core component of the multi-enzyme CoQ-synthome complex essential for mitochondrial metabolism, and its loss or dysfunction leads to marked biochemical and physiological defects.

Other names
2-methoxy-6-polyprenyl-1,4-benzoquinol methylase, mitochondrialUbiquinone biosynthesis methyltransferase COQ5MGC47672-methoxy-6-polyprenyl-1,4-benzoquinol methylaseCOQ10D9COQ5 homolog, methyltransferase
02

Mechanism of action

Drugs that alter COQ5 would affect coenzyme Q10 biosynthesis by inhibiting or modulating methyltransferase activity during the conversion of intermediate benzoquinol substrates in the mitochondrial electron transport chain. (No direct drugs are reported in the sources.)

03

Biological functions

Ubiquinone (coenzyme Q) biosynthesisElectron transport chain functionCellular respirationSAM-dependent methylation
04

Disease associations

Primary coenzyme Q10 deficiency 9Neurodevelopmental disorders (including intellectual disability, encephalopathy, cerebellar ataxia, atrophy, developmental delay)Cardiovascular diseaseKidney diseaseNeurodegenerative disease
05

Safety considerations

Disrupting COQ5 function leads to mitochondrial dysfunction, which can cause multi-system failure including severe neurological, muscular, kidney, and cardiac symptomsNo specific drug safety concerns are reported, but genetic biallelic loss is pathogenic and highly deleterious
06

Biomarkers

COQ10 (coenzyme Q10) levels in tissues and blood as a biomarker for COQ5-related disease states

Beyond the preview

Go deeper on Coenzyme Q5, methyltransferase (COQ5).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Coenzyme Q5, methyltransferase (COQ5).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call